
NYSE:SYK
This summary was created by AI, based on 8 opinions in the last 12 months.
Stryker Corp. (SYK) is a leading player in the medical device sector, particularly in orthopedics, with a notable 70% market share in the U.S. robotics platform. The company, which primarily generates its revenue from the U.S. market, is seen as well-positioned to capitalize on the aging population, as demand for hip, knee, shoulder, and spine procedures increases. Despite recent challenges, including a cybersecurity attack and overall weakness in the health sector, analysts are optimistic about SYK's recovery potential and growth trajectory. Furthermore, Stryker's solid relationships with medical professionals and a consistent dividend increase bolster the investment case. Most analysts express confidence in SYK's ability to achieve substantial earnings per share growth while maintaining an attractive valuation in a growing market.
A manufacturer of medical and surgical devices. The company has had positive sales growth for over 40 years. They do a great job at identifying areas where they are weak, finding a way to fill that gap and executing the strategy quickly. There is not much exposure they hold in China -- fortuitous right now. Yield 1.03% (Analysts’ price target is $232.92)
A great medical equipment company. Over time, they've consolidated and grown. Demographic trends are on his side. But he owns Abbott instead; you can't own everything. Wait for more of a pullback to buy. If the PE falls to the low-$20s, step in.